NeurogesX, Inc. Provides Regulatory Update for NGX-1998 Clinical Program

Published: Aug 07, 2012

SAN MATEO, Calif., Aug. 7, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today provided an update on its regulatory process for NGX-1998, the Company's next generation liquid formulation of prescription-strength capsaicin. NeurogesX recently received End-of-Phase 2 guidance from the U.S. Food and Drug Administration (FDA) regarding its previously announced plans for the Phase 3 clinical development of NGX-1998 as a treatment for neuropathic pain conditions, including key elements of its overall development plan related to manufacturing, applicator development and clinical trial design.

Back to news